|Day Low/High||2.08 / 2.17|
|52 Wk Low/High||0.60 / 2.90|
- Reinhard von Roemeling, M.D., Joins Company as Senior Vice President, Clinical Development -
- Anti-tumor activity observed in multiple patients in initial data from the ongoing Phase 1 study of CA-4948 in non-Hodgkin Lymphoma -
LEXINGTON, Mass., July 30, 2019 /PRNewswire/ -- Curis, Inc.
LEXINGTON, Mass., July 5, 2019 /PRNewswire/ -- Curis, Inc.
Publication demonstrates specific U2AF1 splicing factor mutations induce oncogenic IRAK4-L isoform and activate innate immune pathways in myeloid malignancies
-- Management to host conference call today at 4:30 p.m. EDT --
LEXINGTON, Mass., May 7, 2019 /PRNewswire/ -- Curis, Inc.
LEXINGTON, Mass., May 6, 2019 /PRNewswire/ -- Curis, Inc.
The most recent short interest data was recently released for the 04/30/2018 settlement date, and Curis Inc is one of the most shorted stocks of the Russell 3000, based on 7.52 "days to cover" versus the median component at 5.00. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.
-- Management to host conference call today at 8:30 a.m. EST --
Aurigene Discovery Technologies Limited, a wholly owned subsidiary of Dr.
-- Management to host conference call today at 8:30 a.m. EDT --
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.